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Background: A photoactive hydrophobic agent 1,5-iodonaphthyl-azide (INA), has been previously shown to
completely inactivate the enveloped viruses. INA sequesters into the lipid bilayer of the virus envelope and upon
UV-irradiation bind to the hydrophobic domains of the envelope glycoproteins. In our earlier study, we have shown
that the Venezuelan equine encephalitis virus (VEEV) genomic RNA was also inactivated during the inactivation of
the virus with INA.
Findings: In the present study, we evaluated if the RNA inactivation property of INA can be used to inactivate
non-enveloped RNA viruses. Encephalomyocarditis virus (EMCV) was used as a model non-enveloped virus.
Treatment with INA followed by UV-irradiation resulted in complete inactivation of EMCV. RNA isolated from
INA-inactivated EMCV was non-infectious and INA was found to be associated with the viral RNA genome.
INA-inactivated EMCV induced robust total antibody response. However binding capacity of INA-inactivated EMCV
to neutralizing antibody was inhibited.
Conclusion: This is the first study to show that INA can completely inactivate non-enveloped virus. Our results
suggest that the amino acid composition of the neutralizing epitope may interfere with the protective antibody
response generated by the INA-inactivated non-enveloped virus.
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Conventional methods of preparing chemically inactivated
viral vaccines have several limitations such as denatured
immunogens, short-lived immunity and, in some cases
incomplete inactivation resulting in disease outbreaks in
the vaccinees [1]. We and others have shown earlier that
1,5-iodonaphthyl-azide (INA), a photoactive hydrophobic
alkylating compound, can inactivate enveloped viruses by
covalently binding to the hydrophobic domains of the viral
proteins present in the envelope lipid bilayer [2-11]. We
also demonstrated that the infectious positive sense
ssRNA viral genome of Venezuelan equine encephalitis
virus (VEEV) was inactivated during inactivation by INA
[5]. We hypothesize that in addition to the enveloped vi-
ruses, INA can also inactivate the non-enveloped viruses
by inactivating the viral RNA genome and this property
can be used to develop non-enveloped viral vaccine* Correspondence: radha.maheshwari@usuhs.edu
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unless otherwise stated.candidates. In this study, we used encephalomyocarditis
virus (EMCV) as a non-enveloped virus model. EMCV is
a Cardiovirus in the family Picornaviridae and like VEEV
has a positive sense ssRNA genome. EMCV infects several
animal species like pigs, rodents, cattle, elephants, non-
human primates and humans and cause frequent out-
breaks in the zoo animals [12-17].
EMCV was inactivated using INA (10 μM, 30 μM,
50 μM and 100 μM dose) and UV-irradiation, as de-
scribed before [7]. Briefly, 500 μg of EMCV was passed
through 30 gauge needle mounted on a 1 ml syringe.
Samples were then mixed with desired dose of INA and
incubated for 30 min in the dark at room temperature.
Samples were centrifuged at 1000 rpm for 1 min to re-
move precipitated INA crystals. Supernatant containing
the virus suspension was transferred to a new 1.5 ml clear
wall tube and irradiated for 5 min using 100 W mercury
UV lamp (Osram Sylvania Products Inc., Winchester, KY
and UVP, LLC, Upland, CA) with intermittent vortexing
using the following setup: A clear glass plate filter was
placed immediately in front of the lamp to filter out theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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wavelengths of UV light. A water filter was placed at a dis-
tance of 6–7 cm from the UV lamp to prevent heating of
the samples and the samples were placed 6–7 cm away
from the water filter. A similar set up delivered a UV dose
of 10 mW/cm2.s in the earlier studies [4,9,11]. The follow-
ing control and test groups were taken: Control samples:
(1) PBS only (UN), (2) EMCV only (E), (3) EMCV plus
UV-irradiation (Ei), (4) EMCV plus 1% DMSO (ED), (5)
EMCV plus 1% DMSO plus UV-irradiation (EDi). INA
was dissolved in DMSO, therefore, the maximum concen-
tration of DMSO (1%) achieved with 100 μM INA dose
was used as control. Test samples: (1) EMCV plus INA
(at 10 μM, 30 μM, 50 μM and 100 μM doses of INA and
referred as EI10, EI30, EI50 and EI100, respectively) and (2)
EMCV plus INA plus UV-irradiation (referred as EI10i,
EI30i, EI50i and EI100i, respectively). Inactivation of the
virus was assessed by the combined results of cytopathic
effect (CPE), virus titer in cell supernatants, and EMCV-
3D gene (encoding for the viral polymerase) specific RT-
PCR on total cellular RNA isolated from the infected cell
(Forward primer- 5′ TCCCGTTTGCGGCAGAAAGATT
3′; Reverse primer- 5′ AAGCGGAACATTGCCACCG
AAT 3′).
INA inactivated EMCV and a complete loss of EMCV
infectivity was achieved at 50 and 100 μM dose of INA
combined with the UV-irradiation (Figure 1). 30 μM
INA in combination with UV-irradiation partially inhib-
ited EMCV infectivity. Treatment with INA alone at 50
and 100 μM doses also partially inhibited the infectivity
of EMCV (Figure 1A and B). Inhibition of EMCV infectiv-
ity by INA alone or in combination with UV-irradiation,
in CPE and virus titer assays, may have been observed due
to the limit of detection of virus in these assays. Therefore,
a more sensitive RT-PCR assay for EMCV 3D-gene was
used, which showed that complete inactivation of EMCV
occurred only at 50 and 100 μM dose of INA in com-
bination with UV-irradiation (Figure 1C). Data suggestsFigure 1 Inactivation of EMCV by INA. A) L-cells were infected with viru
and stained with crystal violet. The wells with live cells are stained in blue.
(represented as TCID50/ml) was measured in the supernatant of L-cells infe
least 4 replicates. C) EMCV-3D gene specific RT-PCR was done on RNAs iso
was used as the reference housekeeping gene. UN: Uninfected cells, UD: uthat INA inactivation of EMCV may be dose dependent, but
is not conclusive. Partial inhibition of EMCV by INA alone
observed in this study was different from our earlier studies
with enveloped viruses where no adverse effect of INA alone
was observed on VEEV and CHIKV [5-7]. As both EI50i
and EI100i showed complete inactivation, only EI100i was
used in the remaining experiments.
To evaluate the effect of INA-inactivation on EMCV
genome infectivity, RNA was isolated from untreated
infectious- EMCV (E-RNA) and EI100i (EI100i-RNA)
using the Viral RNA/DNA purification kit (Life Tech-
nologies Inc., Carlsbad, CA). L cell monolayers were
transfected with 100 ng RNA mixed with 3 μl Fugene
HD transfection reagent (Roche Applied Sciences, In-
dianapolis, IN) and 97 μl optiMEM as per manufac-
turer’s protocol. Virus replication in the transfected cells
was evaluated by EMCV 3D-gene expression using a
specific RT-PCR on the RNA isolated from the cells at
48 h post transfection. No virus specific amplification
was observed in the cells transfected with EI100i-RNA
unlike those transfected with E-RNA (Figure 2A). Similar
results were also observed in a parallel experiment, where
virus replication was evaluated by plaque assay in the cell
supernatants at 72 h post transfection (Figure 2B).
To evaluate whether INA directly interacts with the
viral RNA genome during the inactivation process, auto-
radiography was performed with the RNA isolated from
EMCV inactivated with 100 μM of I125-labeled INA.
Virus particles were treated with RNase free DNase
(Promega corp, Madison, WI) before RNA isolation to
eliminate any cellular DNA contamination. RNA sam-
ples (500 ng) were then subjected to electrophoresis on
6% TBE-urea gel followed by silver staining according to
the manufacturer’s instructions (Silver stain kit, Life
Technologies Inc., Carlsbad, CA). Gel was exposed to
the X-ray film to detect I125-labeled INA specific band
and its association with the viral RNA. INA specific
bands were only obtained and co-localized with RNAs preparations at an MOI = 10. At 72 h post infection, cells were fixed
Clear wells indicate cell death due to virus infection. B) Virus titer
cted with control and test samples. The results are representative of at
lated from cells infected with controls or test EMCV samples. GAPDH
nder the detection limit, UV: Ultraviolet rays.
Figure 2 INA binds to the viral RNA and renders it non-infectious in-vitro. (A) L-cells were transfected with RNA isolated from infectious
EMCV (E-RNA) or EI100i (EI100i-RNA) or mock transfected. EMCV-3D gene specific RT-PCR was done on the total RNA isolated from cells after 48 h
post transfection to test for EMCV replication. (B) Virus replication in cell supernatants was measured by standard plaque assay. No virus replication
was detected in the supernatant of the cells transfected with the EI100i-RNA. Virus titer in cells transfected with E-RNA was similar to the samples
infected with control live EMCV virus. C) RNA was isolated from EMCV (E-RNA), EMCV treated with 100 μM I125-labeled INA (EI100-RNA), and EMCV
treated with 100 μM I125-labeled INA in combination with UV (EI100i-RNA). Co-localization of INA with RNA was tested by overlapping silver staining
of RNA (upper panel) with autoradiograph of I125-labeled INA (lower panel). D) RNA isolated from EI100i (EI100i-RNA) was treated with RNase t1 or
Proteinase K to test the binding of INA to EMCV RNA.
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bination with UV-irradiation (EI100i-RNA, Figure 2C).
No such co-localization was observed with the RNA iso-
lated from EMCV treated with INA alone (EI100-RNA,
Figure 2C). EMCV RNA is present in complex with the
VPg protein, which is present at the 5′ end of the viral
genome [18]. To check whether INA is binding to the
VPg protein or to the viral RNA genome, RNA isolated
from the virus preparations were treated with RNase t1
or proteinase K at 37°C for 1 hr. Treatment with pro-
teinase K resulted in slight reduction in the I125
labeled-INA specific band intensity, whereas, treat-
ment with RNase t1 resulted in greater loss in the band
intensity (Figure-2D) indicating the association of INA
with viral RNA. Taken together, these results suggest
that although some of the INA may bind to the viral
VPg protein; a larger percentage of INA binds to the
viral RNA genome and this binding is dependent on
UV-irradiation.
Safety and protective efficacy of EI100i against lethal
challenge was also evaluated in-vivo under two pilot
studies as described in Additional file 1: Figure S1A &
D. All experiments were conducted in accordance with
the Guide for the Care and Use of Laboratory Animals
(Committee on Care And Use of Laboratory Animals of
The Institute of Laboratory Animal Resources, National
Research Council, NIH Publication No. 86-23, revised
1996) and approved by the Uniformed Services Universityof the Health Sciences (USUHS) institutional animal care
and use committee (IACUC). Study-1: 4-5 week old male
CD-1 mice were immunized intraperitoneally (i.p.) with
saline (n = 5) or 108 plaque forming unit (PFU) of EI100i
(n = 10) on Day 0 and Day 14. PFU for inactivated virus
was extrapolated from the PFU value of the live EMCV
stock that was used for the inactivation. Animals were
challenged with 108 PFU of infectious EMCV through
intra-peritoneal (i.p.) route on Day 28 (Additional file 1:
Figure S1A). Study-2: CD-1 male mice (4-5 weeks old)
were immunized with saline (n = 4) or 108 PFU of EI100i
(n = 6) or EI100i mixed with equal volumes of adjuvant
Alhydrogel® (Alum; final Al concentration of 2 mg/ml;
Brenntag Biosector, Fredeikssund, Denmark) (n = 6) on
Day 0, Day 14 and Day 28. Mice were challenged with
2×107 PFU of virulent EMCV through i.p. route on Day
63 (Additional file 1: Figure S1D). Animals were moni-
tored for clinical signs of disease such as weight loss,
ruffled fur, hunched back, lethargy and paralysis and were
euthanized when found moribund. All animals that re-
ceived the immunization with EI100i developed normally
without any clinical symptoms of disease and gained
weight similar to that of the animals in saline control
group (Additional file 1: Figures S1B & E). A robust total
IgG response was observed post immunization indicating
highly immunogenic nature of EI100i (Additional file 1:
Figures S1C & F). Surprisingly, irrespective of the robust
antibody response immunization with EI100i failed to
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(Additional file 2: Table-S1).
To test if inactivation with INA interfered with the
antigenicity of EMCV, binding of EI100i to anti-EMCV
antibody was evaluated. Western blot analysis using a
polyclonal anti-EMCV antibody (1:100; EMCV anti-
serum, Catalog#301-MDV, USDA) revealed four major
bands corresponding to EMCV structural proteins in the
test and the control samples (Figure 3A). Further ana-
lysis using a polyclonal neutralizing anti-EMCV antibody
(1:50; Catalog#315-MDV, USDA APHIS, NVSL, Ames,
IA), however, revealed complete loss of antibody binding
capacity of EI100 and EI100i samples (Figure-3B). Reduc-
tion in the antibody binding capacity after inactivation
with INA has also been reported with enveloped viruses
[6,7,11]. INA is known to bind to cysteine molecules in
a peptide [2,3]. Neutralizing epitope on the capsid pro-
tein, VP1, of EMCV contains 5 cysteine residues [18,19].
We hypothesize that binding of INA to these cysteine
residues may have resulted in masking of the protective
epitopes present on the surface of EMCV. This would
explain the complete loss of binding to the neutralizing
antibodies and failure of EI100i to protect against chal-
lenge with infectious EMCV. Complete loss of binding
of EMCV treated with INA alone (EI100; Figure 3B) was
unexpected as INA in absence of UV has not been re-
ported to bind to the viral proteins [2]. This suggests ei-
ther a non-specific interaction of INA with viral proteins
or interaction via an unknown mechanism and will need
further evaluation.
This is the first study to demonstrate the inactivation
of non-enveloped virus by INA and it’s binding to the
viral genomic RNA, which was dependent on UV-
irradiation. Though the mechanism by which INA bind-
ing results in inactivation of viral RNA is not known, it
may be possible that INA interferes with the interaction
between the viral genomic RNA and the replicationFigure 3 Antigenicity of INA-inactivated EMCV. A) Western blot
analysis using polyclonal anti-EMCV antibody. B) Western blot
analysis using polyclonal neutralizing anti-EMCV antibody.complex during the virus replication process. Since, INA
seems to inactivate viruses by two independent mechan-
ism i.e., targeting viral envelope proteins [2-4] and viral
genomic RNA; this method presents a novel inactivation
strategy for developing second generation inactivated
virus vaccine candidates for both the enveloped and the
non-enveloped viruses. However, its application may be
limited by the non-specific interaction of INA with the
viral proteins, as observed in this study. Application of
INA inactivation method may also be limited for certain
viruses where the protective epitopes consist largely of
cysteine residues and should be considered while using
INA for inactivated viral vaccine development.
Additional files
Additional file 1: Figure S1. In-vivo evaluation of EI100i as vaccine
candidate. Two separate studies were conducted to evaluate the
immunization efficacy and protective response of EI100i against infectious
EMCV challenge. In the first study, no adjuvant was use and two
immunizations were done two weeks apart (A). In the second study,
adjuvant Alum was used and three immunizations, each two weeks apart,
were done (D). The body weight of the animals was monitored weekly till
the end of study 1 (B) and study 2 (E). Animals were bled at pre-determined
time points to evaluate the seroconversion of the animals post immunization.
The total IgG response against EMCV was evaluated by the end-point dilution
method in the serum collected at day 13 and 27 for the study 1 (C) and day
13, 27 and 42 for the study 2 (F). Pre-bled (day -3) and saline administered
mouse serum were used as negative controls. End point titers were
determined at an absorbance greater than or equal to the mean
absorbance for negative controls plus three times the standard deviation.
A significant increase in the total IgG levels was observed after first
immunization and each booster dose in both the studies. No significant
increase in the total antibody was observed in the presence of Alum. Two
tail student’s t-test was used to calculate the significance (p-value: *≤ 0.01,
**≤ 0.001, ***≤ 0.0001). Significance in comparison to the control group is
also indicated (§ p-value≤ 0.01). (TIFF 715 kb)
Additional file 2: Table S1. Protection after immunization with EI100i.
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